BiotechTV - News

CEO Nicki Thompson describes why she believes the company is differentied in the field, and how TRIMTECH's construct is designed to selectively degrade aggregates that cause neurodegeneration.

He describes his background in life sciences investing and shares his take on the current state of the sector.

He describes why a 'one-size-fits-all' approach has caused numerous ophthalmology trials to fail in the past, and why Character believes a precision medicine approach is overdue.

He describes the science behind the platform, which is already being used by Boehringer Ingelheim for cystic fibrosis. AlveoGene has plans to use it for conditions like the surfactant protein deficiencies SP-B & ABCA3, alpha-1 antitrypsin deficiency, and IPF.

Founder and CEO Carlos Bustamante tells BiotechTV's AI Correspondent, Ryan Flinn, about the biobank and why it is important to better understand how diseases can have different profiles across diverse populations. Plus, how AI will play a role in this work.

Mari Anne Snow describes the advantages she sees nanoparticles having over current modalities like viral vectors, LNPs, and others.

He describes the 14th fund that Atlas raised at the end of last year, which was $450 million. Plus, his take on the environment, regulatory changes, China's impact on the sector, and improving biopharma's image.

She describes the idea of leveraging Glyph to achieve oral dosing of medicines in cases where it would not be possible or tolerable. Plus, the lead clinical program, allopregnanolone, how the company thinks about avoiding high placebo responses in trials, and other programs.

He describes the nine patient dose ascending data in AAT deficiency that was historic for being the industry's first in-vivo proof of concept of a gene editor. Plus, what's next for that program and sickle cell, and the decision to do an "over the wall" financing.

She describes the science behind chromatin and gene regulation, previews upcoming preclinical data the company will have at AACR for its lead SMARCA2 program (partnered with Lilly), and discusses what she would like to see out of future phase 1 data.

He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs.

She describes the efforts that government is making to support medical research in the area, shares her thoughts on competition in science and for jobs from China, and her thoughts on how the industry can improve its messaging.

He describes the intratumoral IL-12 program that is in the clinic today, and the preclinical progress Strand is making on its other programs. Plus, his thoughts on the current public perception of mRNA.

He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance of good murine models, and his take on Chinese competition.

Co-Founder and CEO Peter Joyce describes the science behind this, including how the company's lead programs inhibit Endoplasmic Reticulum Associated Proteases (ERAPs). A clinical stage company, he describes Greywolf's clinical experience and fundraising history.

Co-Founder and CEO Michalis Papadakis describes the unmet need for a quick, accurate assessment of stroke damage by front line physicians, who otherwise might not be experts in the area. Plus, moving the technology to lung disease and beyond.

Daniel Faga goes over the recently released rosnilimab RA data and previews a longer-term follow-up that will be out in the second quarter. Plus, ulcerative colitis data that will be out in the fourth quarter and the opportunity there. He also highlights the company's PD-1 for oncology that is commercialized by GSK.

He sets the table for upcoming readouts from Axsome, Vigil Neuro, Verastem, Corvus, and Harmony Biosciences.

CEO Nima Alidoust and CSO Johnny Yu describe Vevo's contribution of 100M cells, plus a 60,000 drug-patient interaction map, that has been combined with Arc's 200M cell gene expression data from 21 different species (scBaseCamp). They explain the size and scale of this now open source atlas, and the potential utility of it to outside researchers.

Jimi Olaghere describes how his life has changed after participating in a clinical trial for the CRISPR based gene therapy for sickle cell disease that is now called CASGEVY. He describes what it was like receiving the treatment, and discusses the need for more awareness and access in the sickle cell community worldwide for this type of treatment.

Founder & CEO John Mulligan describes how he and his team sold an asset using the same science to Roche in 2022 for $250 million when they were Good Therapeutics, and how the follow-on company Bonum aims to test this approach more broadly. He describes how it works, and discusses the initial programs they have chosen, with a LAG3-IL2 being the most advanced.

He discusses the current downturn, they key of being focused, and his preference of investing in people first. Plus, comments on portfolio companies eGenesis and Vir Biotechnology.

Celebrating with the Seattle (and beyond) biotech community.

CEO Jame Mcllroy describes the scientific platform and how it contrasts to other microbiome approaches. A trial in IBS is scheduled to read out immanently.

Professor Dame Anna Dominiczak describes how new technologies are being rolled out in the community equitably, such as digital dermatology, and invites companies to run clinical trials in Scotland.